Fusion Pharmaceuticals

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production center.

Fusion’s deep radiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell.

Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity.

Fusion Pharmaceuticals headquartered in North America, operates in the Biotechnology, Pharmaceutical, Medical, Biopharma, Oncology sector. The company focuses on Biotechnology and has secured $23.1B in funding across 100 round(s). With a team of 101-250 employees, Fusion Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Fusion Pharmaceuticals, raised $25.0M. Discover more about their projects, partnerships, and impact on our platform.